SCHEMBL5547322

SCHEMBL5547322

COCCNC(=O)c1c(O)c2ncc(Cc3ccc(F)cc3)cc2n(Cc2ccccn2)c1=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
LMNA P02545 3/20 0.43
TSHR P16473 3/20 0.43
KDM4E B2RXH2 3/20 0.43
PKM P14618 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
S1PR3 Q99500 7/20 0.42
HTT P42858 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
USP2 O75604 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
CNR2 P34972 4/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5546547 0.91 ALDH1A1 (0.43) ALDH1A1LMNATSHRKDM4EPKM
SCHEMBL5545514 0.89 GRIN1 (0.44) ALDH1A1LMNATSHRKDM4EPKM
SCHEMBL5545455 0.88 ALDH1A1 (0.46) ALDH1A1LMNATSHRKDM4EPKM
SCHEMBL5545366 0.87 L3MBTL1 (0.43) ALDH1A1KDM4EL3MBTL1HTTSMN1; SMN2
SCHEMBL5548095 0.87 L3MBTL1 (0.38) L3MBTL1MAPTGRIN1GRIN2BCNR2
SCHEMBL5538720 0.86 CNR2 (0.43) ALDH1A1LMNATSHRKDM4EPKM
SCHEMBL5548090 0.85 L3MBTL1 (0.42) ALDH1A1LMNATSHRKDM4EL3MBTL1
SCHEMBL4584216 0.85 L3MBTL1 (0.44) LMNATSHRKDM4EL3MBTL1HTT
SCHEMBL5545596 0.85 L3MBTL1 (0.42) ALDH1A1KDM4EL3MBTL1HTTSMN1; SMN2
SCHEMBL5538439 0.85 GRIN2B (0.45) KDM4EL3MBTL1TP53MAPTGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 ALDH1A1 3812/4885LMNA 3503/4885TSHR 4052/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 ALDH1A1 3073/4885LMNA 4134/4885TSHR 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.